Handelsbanken Fonder AB Purchases New Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Handelsbanken Fonder AB bought a new position in shares of Replimune Group, Inc. (NASDAQ:REPL) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,000 shares of the company’s stock, valued at approximately $101,000.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Replimune Group by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,596,119 shares of the company’s stock worth $44,420,000 after acquiring an additional 242,220 shares during the period. Loomis Sayles & Co. L P grew its holdings in Replimune Group by 8.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,290,450 shares of the company’s stock worth $22,080,000 after acquiring an additional 103,223 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Replimune Group by 32.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 378,310 shares of the company’s stock worth $6,473,000 after acquiring an additional 93,364 shares during the period. Vontobel Holding Ltd. acquired a new stake in Replimune Group during the 4th quarter worth $2,575,000. Finally, Sectoral Asset Management Inc. grew its holdings in Replimune Group by 13.6% during the 3rd quarter. Sectoral Asset Management Inc. now owns 271,056 shares of the company’s stock worth $4,638,000 after acquiring an additional 32,515 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Trading Up 5.9 %

Shares of NASDAQ REPL opened at $6.95 on Friday. The company’s fifty day moving average is $7.70 and its 200-day moving average is $8.91. The stock has a market cap of $426.66 million, a price-to-earnings ratio of -2.20 and a beta of 1.25. Replimune Group, Inc. has a twelve month low of $5.86 and a twelve month high of $24.81. The company has a quick ratio of 12.40, a current ratio of 12.40 and a debt-to-equity ratio of 0.16.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, February 8th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.12. Equities research analysts predict that Replimune Group, Inc. will post -3.28 EPS for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.